Description
Encorafenib, marketed under the brand name BRAFTOVI, It is an prescription medication that has been approved encorafenib (Braftovi) for the treatment of metastatic colorectal cancer (CRC) on April 8, 2020. The FDA also approved encorafenib in combination with binimetinib (Mektovi) for the treatment of metastatic non-small cell lung cancer (NSCLC) on October 11, 2023.
What is BRAFTOVI (encorafenib) ?
BRAFTOVI is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test
How to order approved “BRAFTOVI (encorafenib) for Capsules” Medicine?
BRAFTOVI (Encorafenib) is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing BRAFTOVI and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
